CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 195 filers reported holding CLOVIS ONCOLOGY INC in Q3 2018. The put-call ratio across all filers is 0.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $37,230,000 | -26.0% | 1,500,000 | -46.4% | 1.86% | -22.3% |
| Q4 2018 | $50,288,000 | -2.2% | 2,800,000 | +60.0% | 2.39% | +8.5% |
| Q3 2018 | $51,398,000 | +13.0% | 1,750,000 | +75.0% | 2.20% | +25.7% |
| Q2 2018 | $45,470,000 | +4.4% | 1,000,000 | +21.2% | 1.75% | -18.2% |
| Q1 2018 | $43,560,000 | +6.8% | 825,000 | +37.5% | 2.14% | +7.1% |
| Q4 2017 | $40,800,000 | +147.6% | 600,000 | +200.0% | 2.00% | +91.3% |
| Q3 2017 | $16,480,000 | – | 200,000 | – | 1.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $45,630,648,000 | 43.63% |
| EcoR1 Capital, LLC | 384,348 | $21,523,000 | 10.89% |
| Palo Alto Investors LP | 2,102,857 | $117,760,000 | 6.91% |
| NEA Management Company, LLC | 2,279,781 | $127,668,000 | 6.19% |
| Redmile Group, LLC | 721,632 | $40,411,000 | 4.40% |
| Opaleye Management Inc. | 140,000 | $7,840,000 | 3.96% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 790,555 | $44,271,000 | 2.63% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 339,327 | $19,002,000 | 2.31% |
| PFM Health Sciences, LP | 1,725,126 | $96,607,000 | 2.26% |
| HARBOURVEST PARTNERS LLC | 51,037 | $2,858,000 | 1.50% |